HUE044522T2 - Adeno-asszociált vírus konstrukciókat tartalmazó légúti vezetõ sejtek célzására szolgáló kompozíciók - Google Patents
Adeno-asszociált vírus konstrukciókat tartalmazó légúti vezetõ sejtek célzására szolgáló kompozíciókInfo
- Publication number
- HUE044522T2 HUE044522T2 HUE10716723A HUE044522T2 HU E044522 T2 HUE044522 T2 HU E044522T2 HU E10716723 A HUE10716723 A HU E10716723A HU E044522 T2 HUE044522 T2 HU E044522T2
- Authority
- HU
- Hungary
- Prior art keywords
- adeno
- compositions
- associated virus
- airway cells
- virus constructs
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title 1
- 210000005058 airway cell Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17414909P | 2009-04-30 | 2009-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE044522T2 true HUE044522T2 (hu) | 2019-10-28 |
Family
ID=42358394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10716723 HUE044522T2 (hu) | 2009-04-30 | 2010-04-29 | Adeno-asszociált vírus konstrukciókat tartalmazó légúti vezetõ sejtek célzására szolgáló kompozíciók |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10920244B2 (hu) |
| EP (1) | EP2425000B1 (hu) |
| JP (2) | JP6174318B2 (hu) |
| CN (1) | CN102439157B (hu) |
| DK (1) | DK2425000T3 (hu) |
| ES (1) | ES2724122T3 (hu) |
| HU (1) | HUE044522T2 (hu) |
| PL (1) | PL2425000T3 (hu) |
| TR (1) | TR201906398T4 (hu) |
| WO (1) | WO2010127097A1 (hu) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2425000T3 (pl) | 2009-04-30 | 2019-08-30 | The Trustees Of The University Of Pennsylvania | Kompozycje do kierowania komórek przewodzących do dróg oddechowych zawierające konstrukty wirusów związanych z adenowirusami |
| KR101956885B1 (ko) * | 2011-02-17 | 2019-03-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 조직 특이성 변경 및 ａａｖ９-매개 유전자 전달 개선을 위한 조성물 및 방법 |
| DE102013215817A1 (de) | 2013-08-09 | 2015-02-12 | Universitätsklinikum Hamburg-Eppendorf | Neue peptide mit spezifität für die lunge |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| DE102014207498A1 (de) | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3800260A1 (en) * | 2014-09-24 | 2021-04-07 | City of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| US10335466B2 (en) | 2014-11-05 | 2019-07-02 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of parkinson's disease |
| SG10202001102XA (en) | 2014-11-14 | 2020-03-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| CA3006569A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
| RU2764587C2 (ru) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Способы и композиции для лечения хореи гентингтона |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| JP6994018B2 (ja) | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| SG11201909870SA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| EP3619308A4 (en) | 2017-05-05 | 2021-01-27 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR HUNTINGTON'S MORBUS |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| WO2019067840A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | RESTRICTING CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION |
| AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| MX2020008133A (es) | 2018-02-01 | 2020-10-14 | Homology Medicines Inc | Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas. |
| EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof |
| EP3788165A1 (en) | 2018-04-29 | 2021-03-10 | REGENXBIO Inc. | Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles |
| EP3787771A1 (en) | 2018-04-29 | 2021-03-10 | REGENXBIO Inc. | Scalable clarification process for recombinant aav production |
| TW202016314A (zh) | 2018-05-09 | 2020-05-01 | 美商拜奧馬林製藥公司 | 治療苯丙酮尿症之方法 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
| US12060567B2 (en) | 2018-06-13 | 2024-08-13 | Voyager Therapeutics, Inc. | Engineered untranslated regions (UTR) for AAV production |
| JP7385603B2 (ja) | 2018-06-14 | 2023-11-22 | リジェネクスバイオ インコーポレイテッド | 組換えａａｖ生成のためのアニオン交換クロマトグラフィー |
| JP2021530548A (ja) | 2018-07-24 | 2021-11-11 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. | 遺伝子治療製剤を生産するための系および方法 |
| EP3833745A1 (en) | 2018-08-10 | 2021-06-16 | REGENXBIO Inc. | Scalable method for recombinant aav production |
| US20210348242A1 (en) | 2018-10-04 | 2021-11-11 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| EP3861107A1 (en) | 2018-10-05 | 2021-08-11 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| WO2020081415A1 (en) | 2018-10-15 | 2020-04-23 | Regenxbio Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
| EP3867389A1 (en) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
| SG11202103917VA (en) * | 2018-10-16 | 2021-05-28 | Blueallele Llc | Methods for targeted insertion of dna in genes |
| TW202102526A (zh) | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
| ES2965341T3 (es) | 2019-04-11 | 2024-04-12 | Regenxbio Inc | Métodos de cromatografía de exclusión por tamaño para la caracterización de composiciones de virus adenoasociados recombinantes |
| TW202103718A (zh) | 2019-04-19 | 2021-02-01 | 美商銳進科斯生物股份有限公司 | 腺相關病毒載體調配物及方法 |
| KR20220012231A (ko) | 2019-04-24 | 2022-02-03 | 리젠엑스바이오 인크. | 완전-인간 번역 후 변형된 항체 치료제 |
| EP3997225A1 (en) | 2019-07-10 | 2022-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
| WO2021021661A1 (en) | 2019-07-26 | 2021-02-04 | Regenxbio Inc. | Engineered nucleic acid regulatory element and methods of uses thereof |
| WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
| BR112022009895A2 (pt) | 2019-11-28 | 2022-08-09 | Regenxbio Inc | Construtos de terapia de gene de microdistrofina e usos dos mesmos |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| IL299771A (en) | 2020-07-10 | 2023-03-01 | Inst Nat Sante Rech Med | Methods and compounds for the treatment of epilepsy |
| EP4213890A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized lanadelumab and administration thereof |
| WO2022060916A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized antibodies for anti-viral therapy |
| KR20230082614A (ko) | 2020-10-07 | 2023-06-08 | 리젠엑스바이오 인크. | 유전자 요법을 안구 전달하기 위한 아데노-연관 바이러스 |
| WO2022076750A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| EP4236999A1 (en) | 2020-10-28 | 2023-09-06 | RegenxBio Inc. | Vectorized anti-tnf-alfa antibodies for ocular indications |
| WO2022094255A2 (en) | 2020-10-29 | 2022-05-05 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| JP2023548145A (ja) | 2020-10-29 | 2023-11-15 | リジェネックスバイオ インコーポレイテッド | 眼の適応症に対するベクター化ｔｎｆ－アルファアンタゴニスト |
| JP2023548432A (ja) | 2020-11-11 | 2023-11-16 | ヨーロピアン モレキュラー バイオロジー ラボラトリー | 遺伝子療法のための改変ウイルス粒子 |
| JP2023554389A (ja) | 2020-12-16 | 2023-12-27 | リジェネクスバイオ インコーポレイテッド | 組換えアデノ随伴ウイルスウイルス粒子を生成する方法 |
| WO2022147087A1 (en) | 2020-12-29 | 2022-07-07 | Regenxbio Inc. | Tau-specific antibody gene therapy compositions, methods and uses thereof |
| JP2024503895A (ja) | 2021-01-21 | 2024-01-29 | リジェネクスバイオ インコーポレイテッド | 組換えポリペプチド及びウイルスの生成の改善 |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| CA3216744A1 (en) | 2021-04-26 | 2022-11-03 | Regenxbio Inc. | Microdystrophin gene therapy administration for treatment of dystrophinopathies |
| WO2022235614A2 (en) | 2021-05-04 | 2022-11-10 | Regenxbio Inc. | Novel aav vectors and methods and uses thereof |
| WO2022241030A1 (en) | 2021-05-11 | 2022-11-17 | Regenxbio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
| AU2022313258A1 (en) | 2021-07-19 | 2024-02-08 | New York University | Auf1 combination therapies for treatment of muscle degenerative disease |
| WO2023060113A1 (en) | 2021-10-05 | 2023-04-13 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| CN118202060A (zh) | 2021-10-05 | 2024-06-14 | 再生生物股份有限公司 | 用于重组aav生产的组合物和方法 |
| EP4413018A1 (en) | 2021-10-07 | 2024-08-14 | RegenxBio Inc. | Recombinant adeno-associated viruses for targeted delivery |
| WO2023060272A2 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| WO2023077092A1 (en) | 2021-10-28 | 2023-05-04 | Regenxbio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
| WO2023178053A1 (en) | 2022-03-13 | 2023-09-21 | Regenxbio Inc. | Modified muscle-specific promoters |
| WO2023183623A1 (en) | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| WO2023201277A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| TW202400803A (zh) | 2022-05-03 | 2024-01-01 | 美商銳進科斯生物股份有限公司 | 載體化抗補體抗體與補體劑及其投與 |
| TW202417633A (zh) | 2022-05-03 | 2024-05-01 | 美商銳進科斯生物股份有限公司 | 用於眼適應症之載體化抗TNF-α抑制劑 |
| WO2023239627A2 (en) | 2022-06-08 | 2023-12-14 | Regenxbio Inc. | Methods for recombinant aav production |
| WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
| WO2024044725A2 (en) | 2022-08-24 | 2024-02-29 | Regenxbio Inc. | Recombinant adeno-associated viruses and uses thereof |
| WO2024081746A2 (en) | 2022-10-11 | 2024-04-18 | Regenxbio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
| WO2024146935A1 (en) | 2023-01-06 | 2024-07-11 | Institut National de la Santé et de la Recherche Médicale | Intravenous administration of antisense oligonucleotides for the treatment of pain |
| WO2024192281A2 (en) | 2023-03-15 | 2024-09-19 | Regenxbio Inc. | Exon skipping gene therapy constructs, vectors and uses thereof |
| WO2024211780A1 (en) | 2023-04-07 | 2024-10-10 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2024216244A2 (en) | 2023-04-13 | 2024-10-17 | Regenxbio Inc. | Targeting aav capsids, methods of manufacturing and using same |
| WO2024233529A2 (en) | 2023-05-07 | 2024-11-14 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2024238853A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Adeno-associated viruses for ocular delivery of gene therapy |
| WO2024238867A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| WO2024238859A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
| WO2025008406A1 (en) | 2023-07-04 | 2025-01-09 | Institut National de la Santé et de la Recherche Médicale | Antisense oligonucleotides and their use for the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| JP2006075171A (ja) * | 1995-11-09 | 2006-03-23 | Avigen Inc | 組換えａａｖビリオン産生における使用のための補助機能 |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| CA2304168A1 (en) | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| WO2000028004A1 (en) * | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| BRPI0214119B8 (pt) | 2001-11-13 | 2021-05-25 | Univ Pennsylvania | vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus |
| WO2005017101A2 (en) * | 2003-05-19 | 2005-02-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH | Avian adenoassociated virus (aaav) and uses thereof |
| EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| EP2359867B1 (en) * | 2005-04-07 | 2014-10-08 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
| JP2009535339A (ja) | 2006-04-28 | 2009-10-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 低下されたキャプシド免疫原性を有する改変ａａｖベクターおよびその使用 |
| WO2009137006A2 (en) * | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| EP2412721A4 (en) | 2009-03-26 | 2012-08-29 | Univ Tokyo Nat Univ Corp | ANTI-KHV ANTIBODIES (KOÏ HERPESVIRUS) AND ANTIGEN ASSOCIATED |
| PL2425000T3 (pl) * | 2009-04-30 | 2019-08-30 | The Trustees Of The University Of Pennsylvania | Kompozycje do kierowania komórek przewodzących do dróg oddechowych zawierające konstrukty wirusów związanych z adenowirusami |
-
2010
- 2010-04-29 PL PL10716723T patent/PL2425000T3/pl unknown
- 2010-04-29 US US13/266,599 patent/US10920244B2/en not_active Expired - Fee Related
- 2010-04-29 EP EP10716723.1A patent/EP2425000B1/en active Active
- 2010-04-29 CN CN201080019389.4A patent/CN102439157B/zh active Active
- 2010-04-29 JP JP2012508722A patent/JP6174318B2/ja active Active
- 2010-04-29 DK DK10716723.1T patent/DK2425000T3/da active
- 2010-04-29 TR TR2019/06398T patent/TR201906398T4/tr unknown
- 2010-04-29 HU HUE10716723 patent/HUE044522T2/hu unknown
- 2010-04-29 WO PCT/US2010/032943 patent/WO2010127097A1/en active Application Filing
- 2010-04-29 ES ES10716723T patent/ES2724122T3/es active Active
-
2017
- 2017-03-17 JP JP2017052379A patent/JP2017127316A/ja active Pending
-
2021
- 2021-01-14 US US17/149,025 patent/US20210147875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2724122T3 (es) | 2019-09-06 |
| CN102439157B (zh) | 2015-09-16 |
| WO2010127097A1 (en) | 2010-11-04 |
| US20210147875A1 (en) | 2021-05-20 |
| TR201906398T4 (tr) | 2019-05-21 |
| JP6174318B2 (ja) | 2017-08-02 |
| EP2425000A1 (en) | 2012-03-07 |
| DK2425000T3 (da) | 2019-05-13 |
| US20120046349A1 (en) | 2012-02-23 |
| EP2425000B1 (en) | 2019-02-20 |
| US10920244B2 (en) | 2021-02-16 |
| JP2017127316A (ja) | 2017-07-27 |
| CN102439157A (zh) | 2012-05-02 |
| PL2425000T3 (pl) | 2019-08-30 |
| JP2012525150A (ja) | 2012-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2425000T3 (pl) | Kompozycje do kierowania komórek przewodzących do dróg oddechowych zawierające konstrukty wirusów związanych z adenowirusami | |
| HK1252488A1 (zh) | 用於核酸遞送的組合物 | |
| ZA201109375B (en) | Fuel compositions comprising isoprene derivatives | |
| GB201003973D0 (en) | Fuel compositions | |
| HK1171954A1 (zh) | 包含抗炎共混物的組合物 | |
| ZA201106050B (en) | Dye-polymers formulations | |
| EP2651958A4 (en) | Glycoside blends | |
| GB2477038B (en) | Toner compositions | |
| EP2403535A4 (en) | COMPATIBILIZED ELECTROLYTIC FORMULATIONS | |
| IL225415A0 (en) | Electrolytic formulations | |
| GB201019297D0 (en) | Improved compositions | |
| EP2547334A4 (en) | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS | |
| IL269369A (en) | The vehicles are improved | |
| EP2531167A4 (en) | COMPOSITIONS FOR TARGETING HAIRFOLLICLES | |
| SG10201706265PA (en) | Novel compounds and compositions for targeting cancer stem cells | |
| GB0919210D0 (en) | Formulations | |
| IL216351A0 (en) | Casb7439 constructs | |
| GB2475786B (en) | Fuel formulations | |
| EP2558506A4 (en) | GEWEBEANZIELUNG | |
| EP2398462A4 (en) | PH-MODULATED FORMULATIONS FOR PULMONARY ADMINISTRATION | |
| GB2482236B (en) | Toner compositions | |
| GB2477040B (en) | Toner compositions | |
| EP2421952A4 (en) | COMPOSITIONS FOR THE TRANSFECTION OF BIOMOLECULES IN CELLS | |
| GB201019953D0 (en) | Fuel formulations | |
| GB201019966D0 (en) | Fuel formulations |